Orris

Arthritis

Reading File
Asking for Preferences
Finding Sources
Searching PubMed

"rheumatoid arthritis"[MeSH Terms] AND "treatment"[MeSH Terms]

Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Finding Sources
Reading File
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
I now have rich material from Firestein & Kelley's Textbook of Rheumatology. Let me compile a thorough, well-organized answer.

Rheumatoid Arthritis (RA)

Definition & Overview

Rheumatoid arthritis is a chronic, systemic autoimmune disease characterized by symmetric, destructive polyarthritis with highly specific autoantibodies targeting post-translationally modified proteins - primarily anti-citrullinated protein antibodies (ACPAs) and anti-carbamylated protein (anti-CarP) antibodies. It affects approximately 0.5-1% of the population, with a 2-3:1 female-to-male predominance. If untreated, it leads to progressive joint destruction, functional disability, and significant cardiovascular and systemic morbidity.

Pathogenesis

Autoantibody Formation & Citrullination

The central molecular event in RA is citrullination - a post-translational modification converting positively charged arginine to neutral citrulline, catalyzed by calcium-dependent enzymes called peptidyl-arginine deiminases (PADs). In genetically susceptible individuals, this triggers autoimmunity against citrullinated antigens (ACPAs). Key autoantigens include citrullinated collagen type II, fibrinogen, vimentin, and alpha-enolase.
Beyond ACPAs, a new class of anti-modified protein antibodies (AMPAs) has been identified, including anti-malondialdehyde-acetaldehyde, anti-acetylated, and anti-carbamylated protein antibodies.

Immune Complexes & Neutrophil Extracellular Traps (NETs)

Immune complexes of citrullinated antigens and ACPAs display increased immunogenicity and arthritogenicity. Neutrophils are abundant in inflamed joints (especially in synovial effusions in early disease) and form NETs - extracellular chromatin traps that:
  • Release PAD2/PAD4 enzymes, further citrullinating extracellular proteins
  • Activate synovial fibroblast-like synoviocytes (FLS), causing cytokine and chemokine release
  • Present NET-derived peptides via MHC class II to CD4+ T cells, amplifying autoimmune responses
  • Directly damage cartilage matrix via NET-derived elastase
(Firestein & Kelley's Textbook of Rheumatology)

Cytokines

Key pro-inflammatory cytokines include TNF, IL-6, IL-1β, IL-17, IL-12, IL-15, GM-CSF, and G-CSF. These cytokine elevations appear 2-3 years before RA diagnosis in at-risk individuals. IL-6 is particularly notable as it drives the acute phase response through the JAK-STAT3 pathway and is the primary target of tocilizumab and sarilumab.

Platelets

Thrombocytosis correlates with disease severity and relapses, driven by inflammatory cytokines (IL-1, IL-6, TNF). Platelet-leukocyte aggregates, microparticles, soluble P-selectin, and soluble CD40L are elevated in RA blood; platelet microparticles are found in synovial fluid.

Risk Factors & Pre-Clinical Phase

Genetic

  • HLA-DR4 / shared epitope (HLA class II) - the strongest genetic risk factor
  • Multiple RA risk alleles contribute (39 identified in prediction models, AUC ~0.82 for seropositive patients with family history)

Environmental

FactorMechanism
SmokingInduces PAD2/PAD4-mediated citrullination; 57% of smokers vs 7% non-smokers have elevated citrullinated peptides in alveolar compartment; RA-related autoantibodies detectable in sputum of 39% at-risk patients
Periodontal diseasePorphyromonas gingivalis produces PAD enzymes causing citrullination; Tannerella forsythia, Treponema denticola, and A. actinomycetemcomitans modulate host immune responses
Gut microbiomePrevotella copri enrichment found in seropositive patients vs. antibody-negative first-degree relatives (FDRs) and in new-onset untreated RA

Pre-Clinical Staging

RA progression follows defined phases:
  1. Genetic/environmental risk
  2. Systemic autoimmunity (ACPA development)
  3. Symptoms without clinical arthritis (arthralgia)
  4. Classifiable RA
ACPA is the strongest single predictor of progression (HR 3.95 in prospective cohorts). Higher ACPA titers increase RA risk over 3-5 years. Among seropositive FDRs followed for a median 4 years, ~15% progressed to RA.
Prevention trials:
  • StopRA (hydroxychloroquine in earliest pre-classification stage) - halted; showed no benefit
  • PRAIRI (one dose rituximab in seropositive arthralgia) - delayed onset of inflammatory arthritis
  • ARIAA (abatacept 6 months in seropositive arthralgia + positive MRI) - preliminary data suggesting delayed/prevented inflammatory arthritis

Clinical Features

Joints:
  • Symmetric polyarthritis, predominantly small joints of hands and feet (MCPs, PIPs, wrists, MTPs)
  • Morning stiffness lasting >1 hour
  • Ulnar deviation, swan-neck deformities, boutonniere deformities (chronic disease)
  • Atlanto-axial subluxation (cervical spine involvement - important pre-intubation consideration)
Extra-articular manifestations:
  • Rheumatoid nodules (subcutaneous, over extensor surfaces)
  • Interstitial lung disease (ILD), pleuritis
  • Cardiovascular disease (2x increased risk of MI and stroke - the major cause of excess mortality)
  • Felty's syndrome (seropositive RA + splenomegaly + neutropenia)
  • Vasculitis
  • Secondary Sjogren's syndrome
  • Peripheral neuropathy, mononeuritis multiplex

Diagnosis & Classification

2010 ACR/EULAR Classification Criteria (replaced the 1987 criteria): A score of ≥6/10 is required:
DomainPoints
Joint involvement (number and type)0-5
Serology (RF or ACPA negative=0, low positive=2, high positive=3)0-3
Acute phase reactants (CRP/ESR)0-1
Duration of symptoms (≥6 weeks=1)0-1
Serology: RF (rheumatoid factor) and anti-CCP (anti-cyclic citrullinated peptide, equivalent to ACPA) - anti-CCP is more specific (~95%) than RF (~70-80% sensitive, ~80% specific).
Inflammatory markers: CRP and ESR (CRP is now preferred over ESR for monitoring)
Imaging: X-ray (erosions, joint space narrowing - late findings); MRI and ultrasound detect synovitis and erosions earlier

Disease Activity Measurement

InstrumentComponentsRemissionLowModerateHigh
DAS2828 tender/swollen joint counts, patient global, ESR or CRP≤2.6≤3.2>3.2-5.1>5.1
SDAITJC, SJC, provider/patient global, CRP≤3.3≤11>11-26>26
CDAITJC, SJC, provider/patient global (no labs)≤2.8≤10>10-22>22
RAPID3HAQ, pain, patient global≤3≤67-12≥13
(Firestein & Kelley's Textbook of Rheumatology, Table 73.3)
Important caveat: Even patients in clinical remission by these measures often have active disease on MRI or ultrasound. The ACR/EULAR Boolean 2.0 definition (recently updated to allow patient global ≤2.0 cm on 0-10 VAS) improves agreement with index-based remission definitions.

Treatment

Overarching Principles

The paradigm shift in modern RA management:
  1. Early diagnosis and treatment - before irreversible joint damage
  2. Treat-to-target (T2T) - targeting remission or low disease activity, assessed every 1-3 months, escalating treatment until target is reached
  3. DMARDs for virtually all patients - not just symptom control
  4. Increasing MTX use, including subcutaneous administration + folic acid co-administration

The Therapeutic Toolbox

Conventional synthetic DMARDs (csDMARDs):
  • Methotrexate (MTX) - anchor drug and first-line; oral or subcutaneous; always co-administer folic acid
  • Hydroxychloroquine
  • Sulfasalazine
  • Leflunomide
  • Azathioprine, cyclosporine, minocycline (less commonly used)
Biologic DMARDs (bDMARDs) - by target:
TargetDrugs
TNF-alphaEtanercept, Infliximab, Adalimumab*, Golimumab, Certolizumab
CD20 (B cells)Rituximab*
CD80/86 (T cell co-stimulation)Abatacept
IL-6 receptorTocilizumab, Sarilumab
IL-1Anakinra
*Biosimilars available
JAK inhibitors (targeted synthetic DMARDs):
  • Tofacitinib (JAK1/3)
  • Baricitinib (JAK1/2)
  • Upadacitinib (JAK1 selective)

Treatment Strategy (ACR 2021 Guidelines)

  1. MTX monotherapy - start early in almost all patients
  2. If inadequate response (assess at 3 months): add or switch DMARD
    • Triple therapy (MTX + hydroxychloroquine + sulfasalazine) OR
    • MTX + biologic (TNF inhibitor preferred first biologic) OR
    • MTX + JAK inhibitor
  3. Glucocorticoids - bridge therapy at low doses while DMARDs take effect; avoid long-term use
  4. NSAIDs - symptom control only, no disease-modifying effect
  5. Biosimilars are preferred over originators when efficacy/safety are equivalent
Lifestyle modifications (also useful in pre-RA): smoking cessation, Mediterranean-style diet, regular exercise, healthy body weight.

Prognosis & Monitoring

Poor prognostic factors: high ACPA titer, high CCP titer, high baseline disease activity, early erosions, smoking, female sex, multiple swollen joints.
Monitoring includes: disease activity scores every 1-3 months until target; CBC, LFTs, creatinine with MTX; annual CV risk assessment (RA doubles CV risk); bone density (risk of osteoporosis from inflammation and glucocorticoids); ophthalmology screening with hydroxychloroquine (retinopathy).
Sources: Firestein & Kelley's Textbook of Rheumatology, 2-Volume Set; 2010 ACR/EULAR RA Classification Criteria (Aletaha et al., Ann Rheum Dis 2010); 2021 ACR Guideline for Treatment of RA (Fraenkel et al.)
This is a shared conversation. Sign in to Orris to start your own chat.